GANX Gain Therapeutics
- 2.590
- +0.250+10.68%
Gain Therapeutics News
Buy Rating Affirmed for Gain Therapeutics Amidst Promising Clinical Trials and Strong Financial Health
Buy Rating Affirmed for Gain Therapeutics Amid Positive Clinical and Financial Performance
Gain Therapeutics | 10-Q: Quarterly report
Gain Therapeutics' Q1 Cash, Cash Equivalent And Marketable Securities Were $12.7M, With Cash Runway Guidance Into 2025
Gain Therapeutics' Q1 Cash, Cash Equivalent And Marketable Securities Were $12.7M, With Cash Runway Guidance Into 2025
Gain Therapeutics 1Q Loss/Shr 22c >GANX
Gain Therapeutics 1Q Loss/Shr 22c >GANX
Buy Rating Affirmed for Gain Therapeutics on Promising GT-02287 Clinical Progress
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Acrivon Therapeutics, Inc. (ACRV) and Gain Therapeutics (GANX)
Gain Therapeutics Shares Rise 8% After Positive Results From Early Trial of Parkinson's Disease Therapy
By Chris Wack Gain Therapeutics shares rose after the company said it saw positive results from an early study of its potential Parkinson's Disease therapy. Shares were up 8% to $3.65 in early tradi
Gain Therapeutics Reports Results From Single Ascending Dose Part Of Phase 1 Clinical Trial Of GT-02287, Novel GCase-Targeting Small Molecule Therapy For GBA1 Parkinson's Disease
GT-02287 was generally well tolerated up to and including the highest planned dose level, and there were no serious adverse events. The good safety and tolerability profile and the appropriate range o
Oppenheimer Maintains Outperform on Gain Therapeutics, Maintains $9 Price Target
Oppenheimer analyst Hartaj Singh maintains Gain Therapeutics (NASDAQ:GANX) with a Outperform and maintains $9 price target.
Oppenheimer Remains a Buy on Gain Therapeutics (GANX)
Here's Why Gain Therapeutics (GANX) Could Be Great Choice for a Bottom Fisher
Insiders Are Piling Into These 10 Healthcare Stocks in 2024
Gain Therapeutics Welcomes New CFO Gene Mack
Gain Therapeutics Appoints Gene Mack as Chief Financial Officer >GANX
Gain Therapeutics Appoints Gene Mack as Chief Financial Officer >GANX
Gain Therapeutics Bolsters Management Team With the Appointment of Gene Mack as Chief Financial Officer
Gain Therapeutics, Inc. (Nasdaq: GANX) today announces the appointment of Gene Mack, MBA as its chief financial officer, effective as of April 8, 2024.
Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying
The Dow Jones index closed lower by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders int
Director Jeffrey Riley Acquires 30,000 Shares of Gain Therapeutics Inc (GANX)
NVCR, SBNY and VITL Are Among After Hour Movers
Gain Therapeutics(GANX.US) Director Buys US$115.77K in Common Stock
$Gain Therapeutics(GANX.US)$ Director Riley Jeffrey Scott purchased 30,000 shares of Common Stock on Mar 28, 2024 at an average price of $3.859 for a total value of $115.77K.Source: Announcement What
Analysis
Price Target
No Data
